PURPOSE OF REVIEW: New treatment options have been studied over the last several 
years, with a recent approval, a first for Behçet syndrome, in the United 
States. New management guidelines have also been published, helping with this 
nowadays more commonly recognized condition's management. The goal of this 
review is to summarize the most important and potentially clinically relevant 
recent developments and discuss their impact in the management of patients with 
Behçet syndrome.
RECENT FINDINGS: Apremilast is now approved for the treatment of oral ulcer of 
Behçet syndrome in the United States. It's possible benefits in controlling 
nonoral ulcer features of the syndrome are awaited. Long-term use of tumor 
necrosis factor inhibitors for the treatment of especially eye disease in Behçet 
syndrome seems to be safe and efficacious. New treatment options such as 
ustekinumab, secukinumab, tocilizumab and others have early promising data but 
more studies are needed to better clarify their role in Behçet management.
SUMMARY: The last 2 years have not only seen the approval of the first drug 
specifically labeled for the treatment of Behçet syndrome in the case of 
apremilast, many groups have also presented and published their findings on 
promising new therapeutic agents, which may soon be added to our tools in 
treating this condition. We also know more about other drugs, such as tumor 
necrosis factor inhibitors as many patients have been on these for long periods 
of time, and long-term follow-up data seem to confirm their role in Behçet 
treatment. Lack of placebo controlled, randomized trials, for the most part, are 
still outstanding issues.